SUCLG1 and acute myeloid leukemia: Although FLT3 wild-type and mutant cancers present with comparable sensitivity to venetoclax (Konopleva et al, 2022), the levels and activity of SUCLG1, SIRT5, and POLRMT and the potential synergy between venetoclax and SIRT5 inhibitors should be further examined in FL3-IDT AML cases.